In Japan muss in Packungsbeilagen von Augentropfen, die das Glaukommittel Brimonidin (ALPHAGAN u.a.; z.B. in COMBIGAN) enthalten, auf das Risiko für Hornhauttrübungen hingewiesen werden.

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

Jan 12 (Reuters) - AbbVie said on Monday that it has struck a three-year deal with U.S. President Donald Trump’s administration to reduce drug prices, and has pledged $100 billion over the next decade for research and development in the country. The drugmaker said the investment will include manufacturing and will expand direct-to-patient offerings through TrumpRx for widely used medicines such as Alphagan, Combigan, Humira and Synthroid. This three-year agreement provides AbbVie with exemption from tariffs and future pricing mandates, the company said, adding that further terms of the deal remain confidential. The Trump administration has been pressing drugmakers to lower prices, as Americans often pay nearly three times more for prescription medicines than patients in other developed nations. In December, the administration reached agreements with several other major pharmaceutical companies, including Roche, Merck and Gilead, to cut the prices of their medicines for the government’s Medicaid program and for cash-paying consumers. Most Americans with health insurance pay for drugs with set co-pays or co-insurance based on the list price. They may not be helped by TrumpRx, which will direct customers to drugmakers’ websites, where they will sell their products to cash-pay customers. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ABBV plus thousands of other stocks and find your next hidden gem with massive upside.